Gland Pharma Secures USFDA Approval for Generic Depo-Medrol Injectable Suspension
Gland Pharma Ltd 路 Press Release 路 03 Nov 2026, 5:01 pm
Gland Pharma Secures USFDA Approval for Generic Depo-Medrol Injectable Suspension Gland Pharma received USFDA approval for its ANDA for Methylprednisolone Acetate Injectable Suspension USP across single-dose (40 mg/mL, 80 mg/mL) and multiple-dose vials (200 mg/5 mL, 400 mg/10 mL, and 400 mg/5 mL). The product is bioequivalent and therapeutically equivalent to Pfizer's reference listed drug, Depo-Medrol Injectable Suspension, which treats various allergic, dermatologic, endocrine, and respiratory disorders. According to IQVIA data, Methylprednisolone injection generated US sales of approximately USD 214 million for the twelve months ending Aug'26.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 路 09 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
